Elysium Therapeutics Completes Pre-IND Meeting with FDA for First-Ever Technology Designed to Combat Oral Fentanyl Overdose
Reports alignment with FDA on next steps to progress clinical program for SOOPR™ as a potentially novel rescue therapy for oral fentanyl overdose LYONS, Colo., Aug. 20, 2025 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically...
Related Questions
How will the FDA alignment on SOOPR™ affect Elysium Therapeutics' upcoming clinical milestones and timeline?
What is the potential market size and competitive landscape for a novel oral fentanyl overdose rescue therapy?
Could this development trigger a revaluation of Elysium Therapeutics' stock, and what are the expected short‑term and long‑term price implications?